Abstract:CYP2C9 is one of the most abundant CYP enzymes in the human liver ( approximately 20% of hepatic total CYP content). CYP2C9 metabolizes approximately 20% clinical drugs (>120 drugs), including a number of drugs with narrow therapeutic ranges. Some natural compounds are also metabolized, probably leading to the formation of toxic metabolites. CYP2C9 also plays a role in the metabolism of several endogenous compounds such as steroids, melatonin, retinoids and arachidonic acid. Typical substrates of CYP2C9 such as celecoxib, ibuprofen, flurbiprofen, and diclofenac are relatively small, lipophilic and contain acidic groupings with pK(a) values in the range 3.8-8.1 which will be ionized at physiological pH. The carboxylate groups of tienilic acid and diclofenac have been shown to be responsible for substrate preference and orientation in the active site of CYP2C9. Therefore, a typical CYP2C9 substrate should contain an anionic site and a hydrophobic site. However, neutral or positively charged compounds may also be substrates of CYP2C9. CYP2C9 is subject to inhibition by a number of drugs and other compounds and this may provide an explanation for some clinical drug-drug interactions. With regard to prodrugs that need CYP2C9 for activation, inhibition of CYP2C9 may cause a decrease in the amount of the active metabolite, leading to therapeutic failure. Pharmacophore models have revealed that hydrogen bonding, ion-pair interactions, and probably hydrophobic interactions play a major role in determining the substrate specificity and inhibitor selectivity of CYP2C9. A number of structure-activity relationship studies have identified the structural determinants of compounds for their binding affinity to CYP2C9 and inhibitory potency for CYP2C9. Given the critical role of CYP2C9 in drug metabolism and the presence of polymorphisms, it is important to identify drug candidates as potential substrates and/or inhibitors of CYP2C9 in drug development and drugs with minimal interactions with this enzyme should be chosen for further development. Further studies are warranted to explore the molecular determinants for ligand-CYP2C9 binding and the structure-activity relationships.

The cytochrome P450 24A1 interaction with adrenodoxin relies on multiple recognition sites that vary among species

Deciphering Allosteric Coupling Between Substrate Binding and Redox Partner Recognition in Rat CYP24A1, a Vitamin‐D C‐24 Hydroxylase

Substrate 1,25(OH)2D3 and Adrenodoxin Exert a Coordinated Change in CYP24A1 Structure

Interactions of human mitochondrial Ferredoxin 1 (Adrenodoxin) by NMR; modulation by cytochrome P450 substrate and by truncation of the C-terminal tail

Evidence of Allosteric Coupling Between Substrate Binding and Adx Recognition in the Vitamin D Carbon-24 Hydroxylase CYP24A1

Adrenodoxin allosterically alters human cytochrome P450 11B enzymes to accelerate substrate binding and decelerate release

Substrate-induced modulation of protein-protein interactions within human mitochondrial cytochrome P450-dependent system

Phosphorylation Of Bovine Adrenodoxin By Protein Kinase Ck2 Affects The Interaction With Its Redox Partner Cytochrome P450(Scc) (Cyp11a1)

Structural dynamics of cytochrome P450 3A4 in the presence of substrates and cytochrome P450 reductase

Adrenodoxin (adx) and CYP11A1 (p450scc) Induce Apoptosis by the Generation of Reactive Oxygen Species in Mitochondria

Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs

Molecular Characterization of a Class I P450 Electron Transfer System from Novosphingobium Aromaticivorans DSM12444*

New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4

Molecular Characterization of a Class I P450 Electron Transfer System from Novosphingobium aromaticivorans DSM12444

Molecular Determinants of Substrate Affinity and Enzyme Activity of a Cytochrome P450BM3 Variant

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Cross-Linking Mass Spectrometry and Mutagenesis Confirm the Functional Importance of Surface Interactions Between CYP3A4 and Holo/Apo Cytochrome B5

Rat CYP24A1 acts on 20-hydroxyvitamin D(3) producing hydroxylated products with increased biological activity.

Molecular determinant of substrate binding and specificity of cytochrome P450 2J2

Functional Analysis of Human Cytochrome P 450 21 A 2 Variants Involved in Congenital Adrenal Hyperplasia